Moomoo10/09 06:49 UTC
AI Drug Discovery: Is the Next Focus on Experimental Processes? Potential Demand Spillover to DNA Synthesis and Validation Services, and Stocks to Watch
Interest is rising in companies handling DNA synthesis, protein expression and experimental validation as AI drug discovery advances. AI can now design protein, antibody and small-molecule candidates quickly, but experiments are still needed to confirm they work. In an example cited by Ultimator Capital partner Freda Duan, the AI model Claude designed 1,320 protein binders, and 354 were confirmed to bind to the target.
Read the original →